JP2000256176A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JP2000256176A JP2000256176A JP11100462A JP10046299A JP2000256176A JP 2000256176 A JP2000256176 A JP 2000256176A JP 11100462 A JP11100462 A JP 11100462A JP 10046299 A JP10046299 A JP 10046299A JP 2000256176 A JP2000256176 A JP 2000256176A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- parts
- extract
- fruit
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 229940058015 1,3-butylene glycol Drugs 0.000 claims abstract description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 7
- 239000003602 elastase inhibitor Substances 0.000 claims abstract description 7
- 229940122858 Elastase inhibitor Drugs 0.000 claims abstract description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 claims description 11
- 244000077923 Vaccinium vitis idaea Species 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002442 collagenase inhibitor Substances 0.000 claims description 5
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 claims description 4
- 229940122097 Collagenase inhibitor Drugs 0.000 claims description 4
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 4
- 239000002904 solvent Substances 0.000 abstract description 6
- 230000009759 skin aging Effects 0.000 abstract description 5
- 230000037303 wrinkles Effects 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 235000012511 Vaccinium Nutrition 0.000 abstract 3
- 241000736767 Vaccinium Species 0.000 abstract 3
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000002849 elastaseinhibitory effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229950004959 sorbitan oleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- -1 Polyoxyethylene Polymers 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】本発明は、エラスターゼ阻害活性
及び、又はコラーゲン産生促進に基づき、「しわ」をは
じめとする皮膚老化を防止し、あるいは改善する皮膚化
粧料に関する。Detailed Description of the Invention The present invention relates to a skin cosmetic which prevents or improves skin aging such as "wrinkles" based on elastase inhibitory activity and / or promotion of collagen production.
【従来の技術】皮膚は、表皮、真皮、皮下組織の3層に
分けられ、真皮は皮膚の構造・維持に極めて重要であ
り、エラスチン、コラーゲンといった繊維により強固か
つ柔軟に造られ、真皮結合組織を形成している。これら
のエラスチンやコラーゲンといった結合組織の繊維を構
成するタンパク質は、線維芽細胞により合成されてい
る。線維芽細胞は、これらコラーゲン等の繊維と相互作
用することにより、結合組織の状態を制御している。し
かし、皮膚の真皮結合組織が収縮力を失い、さらに強
度、弾性力を失う結果として皮膚がたるみ、しわとなる
と考えられている。近年、この皮膚の老化を防止する多
くの化粧料が知られ、その有効成分としてレチノイン
酸、α−ヒドロキシ酸、レチノール等が報告されてい
る。しかしながら、これらの有効成分は皮膚刺激性や安
定性に問題があり、かつ効果も十分なものであるとは言
い難かった。また、植物抽出物において、エラスターゼ
阻害作用とコラゲナーゼ阻害作用を併せ持つ原料はあま
り知られておらず、また知られていてもそれぞれが顕著
な効果を示すものではなかった。コケモモ(学名:Va
ccinium vitis−idaca L.)はフ
トモモ科の植物で、その果実は古来より食用として用い
られていた。また、その葉の抽出物は頭髪・毛髪化粧料
(登録2122141号、特開平7−196456号)
として作用が確認されていた。2. Description of the Related Art The skin is divided into three layers: epidermis, dermis, and subcutaneous tissue. The dermis is extremely important for the structure and maintenance of the skin, and is made firmly and flexibly by fibers such as elastin and collagen. Is formed. These proteins, such as elastin and collagen, which constitute the fibers of the connective tissue are synthesized by fibroblasts. Fibroblasts control the state of connective tissue by interacting with fibers such as collagen. However, it is believed that the dermis connective tissue of the skin loses contractile force, and further loses strength and elasticity, resulting in sagging and wrinkling of the skin. In recent years, many cosmetics that prevent this skin aging are known, and retinoic acid, α-hydroxy acid, retinol, and the like have been reported as active ingredients. However, these active ingredients have problems in skin irritation and stability, and it has been difficult to say that their effects are sufficient. Also, in plant extracts, raw materials having both elastase inhibitory activity and collagenase inhibitory activity are not well known, and even if they are known, each does not show a remarkable effect. Cowberry (scientific name: Va
ccinium vitis-idaca L .; ) Is a plant of the family Myrtaceae, the fruit of which has been used for food since ancient times. In addition, the extract of the leaves is used for hair and hair cosmetics (Registration No. 2212141, JP-A-7-196456).
The effect was confirmed as.
【発明が解決しようとする課題】そこで本発明の目的
は、エラスターゼ阻害作用及びコラゲナーゼ阻害作用を
有することで、しわ、肌の弾力低下及び肌のくすみの防
止あるいは改善を図る皮膚老化予防に優れ、かつ安全性
や使用感に問題のない化粧料を提供することにある。Accordingly, an object of the present invention is to have an elastase inhibitory action and a collagenase inhibitory action, which are excellent in preventing skin aging for preventing or improving wrinkles, decreased skin elasticity and dull skin, Another object of the present invention is to provide cosmetics having no problem in safety and usability.
【課題を解決するための手段】上記目的の達成に成功し
た皮膚化粧料は、エラスターゼ阻害物質及びコラゲナー
ゼ阻害物質が含まれていることが初めて確認されたコケ
モモの果実に含まれていて、エラスターゼ阻害作用及び
コラゲナーゼ阻害作用を有することを特徴とするもので
ある。Means for Solving the Problems A skin cosmetic which has successfully attained the above-mentioned object is contained in the fruit of a lingonberry which has been confirmed for the first time to contain an elastase inhibitor and a collagenase inhibitor, It has an action and a collagenase inhibitory action.
【発明の実施の形態】本発明の皮膚化粧料の原料となる
コケモモの果実は、コケモモの果実から種子を除いた果
肉部分を使用する。これらの作用促進を促す本体がいか
なるものかは未だに確認されていないが、それは水、メ
タノール、エタノール、プロパノール、1,3−ブチレ
ングリコール又はこれらの混合液を抽出溶媒とする抽出
処理により容易に抽出されてくる。エラスターゼ阻害物
質及びコラゲナーゼ阻害物質を抽出するにあたり、特殊
な抽出方法を採用する必要はなく、室温ないし70℃の
加熱下に任意の装置を用いて抽出することが出来る。簡
単には、抽出溶媒を満たした処理槽に抽出原料を投入
し、時々攪拌して可溶性成分を溶出させる。その後、ろ
過して抽出残渣を取り除き抽出液を得る。得られた抽出
液はそのままでも本発明の皮膚化粧料の原料として使用
することが出来るが、濃縮・乾燥して剤型にすることも
出来る。上述のようにして得られた抽出液又は抽出物
は、コケモモ特有の芳香を有しているため、皮膚化粧料
として利用可能である。また、コケモモの果実は生食用
としても用いられるため、生産量が多く、原料供給にお
ける心配がない。皮膚化粧料に関する本発明の抽出物の
公的配合率は、未精製の標準的な抽出物からなるものの
場合、乾燥物に換算して0.01〜10重量%である。BEST MODE FOR CARRYING OUT THE INVENTION The berry of lingonberry, which is a raw material of the skin cosmetic of the present invention, uses a pulp portion obtained by removing seeds from the lingonberry. Although it has not yet been confirmed what kind of body promotes these actions, it can be easily extracted by an extraction treatment using water, methanol, ethanol, propanol, 1,3-butylene glycol or a mixture thereof as an extraction solvent. Will be. In extracting the elastase inhibitor and the collagenase inhibitor, it is not necessary to employ a special extraction method, and the extraction can be performed using an arbitrary apparatus while heating at room temperature to 70 ° C. Briefly, an extraction raw material is put into a treatment tank filled with an extraction solvent, and stirred occasionally to elute a soluble component. Thereafter, the residue is filtered to remove the extraction residue to obtain an extract. The obtained extract can be used as it is as a raw material of the skin cosmetic of the present invention, but it can also be concentrated and dried into a dosage form. Since the extract or extract obtained as described above has a fragrance peculiar to lingonberry, it can be used as a skin cosmetic. In addition, since the lingonberry fruit is also used for raw food, the production amount is large and there is no concern about the supply of raw materials. The official blending ratio of the extract of the present invention with respect to skin cosmetics is 0.01 to 10% by weight in terms of dry matter in the case of an unrefined standard extract.
【実施例】以下に実施例を示し、本発明をさらに詳細に
説明する。製造実施例 1 コケモモの果実の種子を取り除いた部分500gに水又
は80重量%エタノール又は80重量%メタノール又は
50重量%プロパノール(以下50%PG)又は50重
量%1,3−ブチレングリコール(以下50%BG)を
それぞれ3,000ml加え、70℃に保温しながら3
時間ゆるやかに攪拌したのち、ろ紙を用いてろ過し、抽
出液を得た。この抽出液を35℃で減圧濃縮した後、減
圧乾燥機で乾燥させ乾燥抽出物(以下抽出物とする)を
得た。 〈表 1〉抽出物収率抽出溶媒 抽出物収率(%) 水 12.3 80%エタノール 10.9 80%メタノール 14.8 50%PG 8.5 50%BG 7.3試験実施例 1 エラスターゼ活性阻害作用 試料溶液の調製法:製造実施例1に記載した各抽出物を
エタノールに溶解し、阻害濃度(IC50)を求めるた
め、3段階の濃度に振り分けて以下の試験に供した。 96穴マイクロプレートを使用し、1穴に対して試料溶
液50μl及び酵素50μlを添加する。(このときの
酵素は、エラスターゼタイプIII(シグマ社製)5m
gを0.2Mトリス塩酸緩衝液(pH8.0)1mlに
溶解させストック液とし、−20℃で保存する。(使用
時には緩衝液で250倍希釈したものを使用する)対照
として、酵素の代わりに0.2Mトリス塩酸緩衝液を添
加したものを用意する。さらに基質[N−SUCCIN
YL−ALA−ALA−ALA−p−NITROANI
LIDE(シグマ社製)をDMSOで溶解させ45.1
4mg/mlとして貯蔵液とする。使用時にはトリス塩
酸緩衝液で100倍希釈し1mM溶液として使用する]
100μlを添加して混合し、25℃、50分間反応さ
せ、波長415nmにおける吸光度を測定する。 阻害率(%)={1−(C−D)/(A−B)}×10
0 A:試料無添加、酵素添加時の吸光度 B:試料無添加、酵素無添加時の吸光度 C:試料添加、酵素添加時の吸光度 D:試料添加、酵素無添加時の吸光度 試料溶液の濃度を種々変更して上記阻害率の測定を行
い、エラスターゼ活性を50%阻害する試料溶液濃度を
内挿法により求める。 〈表 2〉試験結果抽出溶媒 50%阻害濃度(ppm) 水 58.6 80%エタノール 45.5 80%メタノール 60.3 50%PG 85.3 50%BG 75.9試験実施例 2 コラゲナーゼ阻害活性 基質:Pz−ペプチド(Pz−Pro−Leu−Gly
−Pro−D−Arg−OH;BACHEM Feni
chemikalien AG社製)0.39mgに対
して、0.1Mトリス塩酸緩衝液(pH7.1、含20
mM塩化カルシウム)1mlに溶解させて(0.5Mに
相当)使用した。なお、切断部位はLeuとProの間
である。 酵素:コラゲナーゼタイプIV(シグマ社製)5mgを
水1mlに溶解させ100μlずつを分注し、−20℃
で保管する。使用時に100μlに水4.9mlを加え
て50倍に希釈して反応に用いる。 試験法:試料溶液50μl、酵素溶液50μl及び基質
溶液400μlを加え、37℃で30分間インキュベー
ションする。その後、25mMクエン酸溶液1mlで反
応を停止し、酢酸エチル5mlで抽出する。遠心分離
(3,000rpm,10分間)後、酢酸エチル分画の
波長320nmにおける吸光度(A)を酢酸エチルを対
照として測定した。別に、酵素溶液の代わりに蒸溜水を
用い、同様に操作したものを空試験(B)とした。ま
た、試料溶液の代わりに蒸溜水を用い、同様に操作した
ものを(C)とした。また、(C)の空試験を(D)と
した。 阻害率(%)={1−(A−B)/(C−D)}×10
0 A:試料添加、酵素添加時の吸光度 B:試料添加、酵素無添加時の吸光度 C:試料無添加、酵素添加時の吸光度 D:試料無添加、酵素無添加時の吸光度 試料溶液の濃度を種々変更して上記阻害率の測定を行
い、コラゲナーゼ活性を50%阻害する試料溶液濃度を
内挿法により求める。 〈表 3〉試験結果抽出溶媒 50%阻害濃度(ppm) 水 98.0 80%エタノール 120.5 80%メタノール 112.5 50%PG 118.0 50%BG 122.5製剤実施例 1 製造実施例1で製造した乾燥抽出物を用いて乳液を製造
した。 ステアリン酸 2部 スクワラン 2部 オリーブ油 2部 セタノール 7部 ホホバ油 2部 ポリオキシエチレン(40E.O.)硬化ヒマシ油 1部 グリセリン 10部 製造実施例1の水抽出物 3部 精製水 残部(全量を100部とする)製剤実施例 2 製造実施例1で製造した乾燥抽出物を用いて化粧水を製
造した。 グリセリン 10部 1,3−ブチレングリコール 3部 オレイン酸ポリオキシエチレンソルビタン(20E.O.)3部 パラオキシ安息香酸メチル 0.5部 クエン酸 0.1部 クエン酸ナトリウム 1部 香料 0.05部 製造実施例1の80%エタノール抽出物 3部 精製水 残部(全量を100部とする)製剤実施例 3 製造実施例1で製造した乾燥抽出物を用いてクリームを
製造した。 流動パラフィン 5部 サラシミツロウ 4部 セタノール 3部 スクワラン 10部 ラノリン 2部 ステアリン酸 1部 オレイン酸ポリオキシエチレンソルビタン(20E.O.)3部 モノステアリン酸グリセリル 3部 1,3−ブチレングリコール 3部 パラオキシ安息香酸メチル 0.5部 香料 0.05部 製造実施例1の50%PG抽出物 1部 製造実施例1の50%BG抽出物 1部 精製水 残部(全量を100部とする)製剤使用実施例 29歳から48歳までの女性10名に製造実施例2の化
粧料を使用するグループ(グループA)、製造実施例2
の化粧料からコケモモの抽出物を除いたものを使用する
グループ(グループB)に分け、朝夕1日2回、3ケ月
間使用させた。〈表 4〉グループA製剤使用結果 〈表 5〉グループB製剤使用結果 The present invention will be described in more detail with reference to the following examples. Production Example 1 Water or 80% by weight ethanol or 80% by weight methanol or 50% by weight propanol (hereinafter 50% PG) or 50% by weight 1,3-butylene glycol (hereinafter 50) % BG) and add 3 ml while keeping the temperature at 70 ° C.
After gentle stirring for a time, the mixture was filtered using a filter paper to obtain an extract. The extract was concentrated under reduced pressure at 35 ° C., and dried in a vacuum drier to obtain a dry extract (hereinafter referred to as extract). <Table 1> Extract Yield Extraction Solvent Extract Yield (%) Water 12.3 80% Ethanol 10.9 80% Methanol 14.8 50% PG 8.5 50% BG 7.3 Test Example 1 Elastase Activity inhibitory activity Preparation of sample solution: Each extract described in Production Example 1 was dissolved in ethanol, and divided into three concentrations to determine the inhibitory concentration (IC50) and subjected to the following tests. Using a 96-well microplate, add 50 μl of sample solution and 50 μl of enzyme to each well. (Enzyme at this time is elastase type III (Sigma) 5m
g was dissolved in 1 ml of 0.2 M Tris-HCl buffer (pH 8.0) to obtain a stock solution, and stored at -20 ° C. As a control, a 0.2 M Tris-HCl buffer was added instead of the enzyme. Further, the substrate [N-SUCCIN
YL-ALA-ALA-ALA-p-NITROANI
LIDE (manufactured by Sigma) was dissolved in DMSO and 45.1 was dissolved.
Use it as a stock solution at 4 mg / ml. When used, dilute 100-fold with Tris-HCl buffer and use as 1 mM solution.]
100 μl is added and mixed, reacted at 25 ° C. for 50 minutes, and the absorbance at a wavelength of 415 nm is measured. Inhibition rate (%) = {1- (CD) / (AB)} × 10
0 A: Absorbance when no sample is added and enzyme is added B: Absorbance when no sample is added and enzyme is not added C: Absorbance when sample is added and enzyme is added D: Absorbance when sample is added and enzyme is not added The inhibition rate is measured with various changes, and the concentration of the sample solution that inhibits elastase activity by 50% is determined by interpolation. <Table 2> Test results Extraction solvent 50% inhibitory concentration (ppm) Water 58.6 80% Ethanol 45.5 80% Methanol 60.3 50% PG 85.3 50% BG 75.9 Test Example 2 Collagenase inhibitory activity Substrate: Pz-peptide (Pz-Pro-Leu-Gly
-Pro-D-Arg-OH; BACHEM Feni
ChemMalien AG (0.39 mg) and 0.1 M Tris-HCl buffer (pH 7.1, containing 20)
1 mM (equivalent to 0.5 M). The cleavage site is between Leu and Pro. Enzyme: 5 mg of collagenase type IV (manufactured by Sigma) is dissolved in 1 ml of water, and 100 μl each is dispensed at −20 ° C.
Keep in. At the time of use, 4.9 ml of water is added to 100 μl and diluted 50-fold for use in the reaction. Test method: Add 50 μl of sample solution, 50 μl of enzyme solution and 400 μl of substrate solution, and incubate at 37 ° C. for 30 minutes. Thereafter, the reaction is stopped with 1 ml of a 25 mM citric acid solution and extracted with 5 ml of ethyl acetate. After centrifugation (3,000 rpm, 10 minutes), the absorbance (A) of the ethyl acetate fraction at a wavelength of 320 nm was measured using ethyl acetate as a control. Separately, distilled water was used in place of the enzyme solution, and the same operation was carried out to make a blank test (B). Further, distilled water was used in place of the sample solution, and the same operation was made as (C). The blank test of (C) was taken as (D). Inhibition rate (%) = {1- (AB) / (CD)} × 10
0 A: Absorbance when sample is added and enzyme added B: Absorbance when sample is added and enzyme is not added C: Absorbance when sample is not added and enzyme is added D: Absorbance when sample is not added and enzyme is not added The inhibition rate is measured with various changes, and the concentration of the sample solution that inhibits collagenase activity by 50% is determined by interpolation. <Table 3> Test results Extraction solvent 50% Inhibitory concentration (ppm) Water 98.0 80% Ethanol 120.5 80% Methanol 112.5 50% PG 118.0 50% BG 122.5 Formulation Example 1 Production Example An emulsion was prepared using the dried extract prepared in 1. Stearic acid 2 parts Squalane 2 parts Olive oil 2 parts Cetanol 7 parts Jojoba oil 2 parts Polyoxyethylene (40EO) hydrogenated castor oil 1 part Glycerin 10 parts Water extract of Production Example 1 3 parts Purified water Preparation Example 2 A lotion was prepared using the dry extract prepared in Preparation Example 1. Glycerin 10 parts 1,3-butylene glycol 3 parts Polyoxyethylene sorbitan oleate (20EO) 3 parts Methyl parahydroxybenzoate 0.5 parts Citric acid 0.1 parts Sodium citrate 1 part Fragrance 0.05 parts Production 3 parts of 80% ethanol extract of Example 1 Purified water Remainder (total amount is 100 parts) Formulation Example 3 Preparation A cream was prepared using the dry extract prepared in Example 1. Liquid paraffin 5 parts Salami beeswax 4 parts Cetanol 3 parts Squalane 10 parts Lanolin 2 parts Stearic acid 1 part Polyoxyethylene sorbitan oleate (20EO) 3 parts Glyceryl monostearate 3 parts 1,3-butylene glycol 3 parts Paraoxyl 50% PG extract 1 part 50% BG extract 1 part purified water balance of example 1 benzoate 0.5 parts perfume, 0.05 parts preparation example 1 (100 parts total) formulation using practice EXAMPLE Group 10 using the cosmetics of Production Example 2 for 10 women between the ages of 29 and 48 (Group A), Production Example 2
Was divided into groups (group B) using the same composition except for the extract of lingonberry and used twice a day in the morning and evening for 3 months. <Table 4> Group A formulation use results <Table 5> Group B formulation use results
【発明の効果】本発明の皮膚化粧料は、滑らかな肌を与
え、しわをはじめとする皮膚老化を防止し、あるいは改
善することに優れた効果を有するものである。Industrial Applicability The skin cosmetic of the present invention has an excellent effect on providing smooth skin and preventing or improving skin aging such as wrinkles.
Claims (7)
阻害物質を有効成分とすることを特徴とするエラスター
ゼ阻害剤。1. An elastase inhibitor comprising an elastase inhibitor extracted from lingonberry fruits as an active ingredient.
ノール、プロパノール、1,3−ブチレングリコール又
はこれらの混合液により抽出処理して得られた抽出物を
有効成分として含有することを特徴とするエラスターゼ
阻害剤。2. An extract obtained by extracting a lingonberry fruit with water, methanol, ethanol, propanol, 1,3-butylene glycol or a mixture thereof, as an active ingredient. Elastase inhibitors.
阻害物質を有効成分とすることを特徴とするコラゲナー
ゼ阻害剤。3. A collagenase inhibitor comprising, as an active ingredient, a collagenase inhibitor extracted from lingonberry fruits.
ノール、プロパノール、1,3−ブチレングリコール又
はこれらの混合液により抽出処理して得られた抽出物を
有効成分として含有することを特徴とするコラゲナーゼ
阻害剤。4. An extract obtained by extracting a lingonberry fruit with water, methanol, ethanol, propanol, 1,3-butylene glycol or a mixture thereof, as an active ingredient. Collagenase inhibitors.
る皮膚化粧料。(5) A skin cosmetic comprising (1) and (2).
る皮膚化粧料。(6) A skin cosmetic comprising (3) and (4).
特徴とする皮膚化粧料。7. A skin cosmetic comprising the composition of claim 1, 2, 3, or 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11100462A JP2000256176A (en) | 1999-03-02 | 1999-03-02 | Skin cosmetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11100462A JP2000256176A (en) | 1999-03-02 | 1999-03-02 | Skin cosmetic |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000256176A true JP2000256176A (en) | 2000-09-19 |
Family
ID=14274585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11100462A Pending JP2000256176A (en) | 1999-03-02 | 1999-03-02 | Skin cosmetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2000256176A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1195156A1 (en) * | 2000-10-05 | 2002-04-10 | L'oreal | Use of an ericaceae extract in skin-ageing treatment |
WO2001045648A3 (en) * | 1999-12-21 | 2002-04-11 | Oreal | Use of a vaccinium-type extract as an anti-glycation agent |
JP2002363057A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor or cosmetic composition |
JP2003002820A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
EP1314420A1 (en) * | 2001-11-23 | 2003-05-28 | Cognis Iberia, S.L. | Anti-ageing composition |
KR100580858B1 (en) | 2004-08-27 | 2006-05-17 | 로제화장품 주식회사 | Cosmetic composition containing natural products related to ten longevity (Lycra, Ganoderma Lucidum, Quercus variabilis, Antler, Jar, Germanium, Royal jelly, Red ginseng, Salmon roe and Lemon) |
FR2887148A1 (en) * | 2005-06-17 | 2006-12-22 | Silab Sa | Preparing active ingredient useful to fight against skin aging, comprises solubilizing Vaccinium vitis idaea leaves/fruits powder, enzymatic hydrolysis, separating (in)soluble phases, inactivating enzymatic activity, (sterilized) filtering |
WO2009003352A1 (en) * | 2007-07-04 | 2009-01-08 | Beijing Gingko Group | An extract of vaccinium vitis idaea l. and pharmaceutical composition, cosmetic composition, food and use thereof |
JP5062922B2 (en) * | 2011-02-14 | 2012-10-31 | 株式会社J−オイルミルズ | Skin collagen production promoter |
EP2033528A3 (en) * | 2007-07-04 | 2012-12-26 | Beijing Gingko Group Biological Technology Co., Ltd. | Lingonberry extract, the preparing method and use thereof |
WO2014068190A3 (en) * | 2012-11-01 | 2014-12-31 | Lumene Oy | Cosmetic compositions containing fractions of lingonberry extracts |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06153976A (en) * | 1992-11-30 | 1994-06-03 | Kikkoman Corp | Production of phenol glycoside |
JPH07206665A (en) * | 1994-01-13 | 1995-08-08 | Lion Corp | Bathing agent composition |
JPH08104628A (en) * | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | Matrix metalloprotease inhibitor |
JPH08268837A (en) * | 1995-03-31 | 1996-10-15 | Lion Corp | Emulsion-type composition |
JPH11299452A (en) * | 1998-04-20 | 1999-11-02 | Hoometto:Kk | Proanthocyanidin containing nutritive liquid and its production |
-
1999
- 1999-03-02 JP JP11100462A patent/JP2000256176A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06153976A (en) * | 1992-11-30 | 1994-06-03 | Kikkoman Corp | Production of phenol glycoside |
JPH07206665A (en) * | 1994-01-13 | 1995-08-08 | Lion Corp | Bathing agent composition |
JPH08104628A (en) * | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | Matrix metalloprotease inhibitor |
JPH08268837A (en) * | 1995-03-31 | 1996-10-15 | Lion Corp | Emulsion-type composition |
JPH11299452A (en) * | 1998-04-20 | 1999-11-02 | Hoometto:Kk | Proanthocyanidin containing nutritive liquid and its production |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004505007A (en) * | 1999-12-21 | 2004-02-19 | ロレアル | Use of at least one extract of Vaccinium as an anti-glycation agent |
WO2001045648A3 (en) * | 1999-12-21 | 2002-04-11 | Oreal | Use of a vaccinium-type extract as an anti-glycation agent |
FR2814950A1 (en) * | 2000-10-05 | 2002-04-12 | Oreal | USE OF AT LEAST ONE EXTRACT FROM AT LEAST ONE PLANT OF THE ERICACEAE FAMILY IN COMPOSITIONS INTENDED TO TREAT THE SKIN SIGNS OF AGING |
EP1195156A1 (en) * | 2000-10-05 | 2002-04-10 | L'oreal | Use of an ericaceae extract in skin-ageing treatment |
EP2044928A1 (en) * | 2000-10-05 | 2009-04-08 | L'Oreal | Use of at least one extract of at least one plant of the Ericaceae family in compositions intended for treating signs of skin ageing |
US7470438B1 (en) | 2000-10-05 | 2008-12-30 | L'oreal | Ericacea extracts for combating skin aging |
JP2002363057A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor or cosmetic composition |
JP2003002820A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
WO2003043595A1 (en) * | 2001-11-23 | 2003-05-30 | Cognis Iberia, S.L. | Anti-aging agents |
EP1314420A1 (en) * | 2001-11-23 | 2003-05-28 | Cognis Iberia, S.L. | Anti-ageing composition |
KR100580858B1 (en) | 2004-08-27 | 2006-05-17 | 로제화장품 주식회사 | Cosmetic composition containing natural products related to ten longevity (Lycra, Ganoderma Lucidum, Quercus variabilis, Antler, Jar, Germanium, Royal jelly, Red ginseng, Salmon roe and Lemon) |
FR2887148A1 (en) * | 2005-06-17 | 2006-12-22 | Silab Sa | Preparing active ingredient useful to fight against skin aging, comprises solubilizing Vaccinium vitis idaea leaves/fruits powder, enzymatic hydrolysis, separating (in)soluble phases, inactivating enzymatic activity, (sterilized) filtering |
WO2009003352A1 (en) * | 2007-07-04 | 2009-01-08 | Beijing Gingko Group | An extract of vaccinium vitis idaea l. and pharmaceutical composition, cosmetic composition, food and use thereof |
EP2033528A3 (en) * | 2007-07-04 | 2012-12-26 | Beijing Gingko Group Biological Technology Co., Ltd. | Lingonberry extract, the preparing method and use thereof |
JP5062922B2 (en) * | 2011-02-14 | 2012-10-31 | 株式会社J−オイルミルズ | Skin collagen production promoter |
WO2014068190A3 (en) * | 2012-11-01 | 2014-12-31 | Lumene Oy | Cosmetic compositions containing fractions of lingonberry extracts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2654762B1 (en) | Extract of the aerial parts of gynandropsis gynandra and cosmetic, dermatoligic and pharmaceutic compositions comprising the extract | |
WO2012085226A1 (en) | Extract of aerial parts of maca rich in polyphenols and composition comprising same | |
JP3635081B2 (en) | Whitening agents, antioxidants, collagenase activity inhibitors, hyaluronidase activity inhibitors, anti-aging agents, external preparations for skin, cosmetics and foods | |
JP2021509413A (en) | Kapok tree flower extract and cosmetological, pharmaceutical or dermatological compositions containing it | |
JP2006124350A (en) | Nmf production promoter | |
JP2003081749A (en) | Skin care preparation | |
JP2000256176A (en) | Skin cosmetic | |
JPH08259431A (en) | Maillard reaction inhibitor and dermal preparation for external use containing the same | |
JP2002370922A (en) | Cosmetics containing plum extract | |
JP2001302439A (en) | Cosmetic comprising extract extracted from prenus persia batsh | |
JP4460420B2 (en) | Collagen production promoter | |
JP5138262B2 (en) | Topical skin preparation | |
JP2007191452A (en) | Estrogen-like active agent | |
EP2519223A1 (en) | An agent for stimulating the expression of loxl | |
JP4247091B2 (en) | Skin anti-aging agent | |
JP5144362B2 (en) | Topical skin preparation | |
JP2020002053A (en) | Collagen production promoter, MMP inhibitor, melanin production inhibitor, cell growth promoter, antioxidant, wrinkle improver, pharmaceutical or food composition | |
JP2002029923A (en) | Collagen production promoter, elastase activity inhibitor, collagen activity inhibitor and skin cosmetic | |
JP2008074743A (en) | Humectant, cell activator, antioxidant, protease activity promoter, antiageing agent, whitening agent, anti-inflammatory agent, neutral fat accumulation inhibitor | |
JP7479038B2 (en) | Peptidylarginine deiminase 1 expression promoter | |
JP2003095857A (en) | Skin care preparation | |
JP2022072468A (en) | External preparation for skin | |
JP2002029996A (en) | Proteasome activation accelerator | |
JP7597353B2 (en) | Melanin production inhibitors, collagen production promoters, hyaluronic acid production promoters, MMP-2 inhibitors and internal medicines | |
KR102257089B1 (en) | Cosmetic composition for moisturizing comprising diphylleia grayi extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050228 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050422 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050912 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051208 |